Shiraz Organ Transplantation Research Center, Nemazee Hospital, Shiraz University of Medical Sciences, Shiraz, Iran.
Student Research Committee, Faculty of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Arch Iran Med. 2018 Apr 1;21(4):158-163.
Treatment of peritoneal metastases has gained interest among oncologic communities around the world. Cytoreductive surgery (CRS) and hyperthermic intraoperative chemotherapy (HIPEC) have come to be the treatment of choice for selected patients with peritoneal carcinomatosis (PC) in recent years. Prior to HIPEC, patients were treated with palliative support and only guaranteed a few months to live. We reviewed our first 30 patients who underwent CRS and HIPEC. The aim of the study was assessment of the patients' survival, morbidity, and mortality rate and identifying prognostic factors of patients treated with CRS and HIPEC.
In this cross-sectional study, data were retrospectively collected from 45 patients (15 men and 30 women) who underwent CRS and HIPEC between December 2008 and October 2016, at Nemaazi educational hospital and Shiraz central hospital of Shiraz University of Medical Sciences. Peri-operative and regular follow-up data on survival and complications were gathered and analyzed to identify their prognostic value for survival.
The mean age of the patients was 49.7±16.46 years. The participants in this study consisted of 19 females (63.3%) and 11 males (36.7%). The most common primary tumor was ovarian cancer (30.1%). A completeness of cytoreduction score of CC0/CC1 was obtained in 80% of patients operated on with curative intent. The overall mortality rate was 20%. The 1- and 4-year overall survival (OS) were 89% and 54%, respectively.
CRS and HIPEC are most successful in treatment of selected patients. Development of complete resection with CRS in these 8 years and good OS in our patients encourage us to continue the procedure with all its difficulties and cost.
治疗腹膜转移已引起世界各地肿瘤学界的关注。近年来，细胞减灭术（CRS）和腹腔内热化疗（HIPEC）已成为腹膜癌（PC）患者的首选治疗方法。在 HIPEC 之前，患者接受姑息性支持治疗，预期寿命仅为数月。我们回顾了 30 名接受 CRS 和 HIPEC 治疗的患者。本研究的目的是评估患者的生存率、发病率和死亡率，并确定接受 CRS 和 HIPEC 治疗的患者的预后因素。
在这项横断面研究中，我们回顾性收集了 2008 年 12 月至 2016 年 10 月期间在 Nemaazi 教育医院和 Shiraz 医科大学 Shiraz 中央医院接受 CRS 和 HIPEC 治疗的 45 名患者（15 名男性和 30 名女性）的数据。收集并分析围手术期和定期随访的生存和并发症数据，以确定其对生存的预后价值。
患者的平均年龄为 49.7±16.46 岁。本研究的参与者包括 19 名女性（63.3%）和 11 名男性（36.7%）。最常见的原发肿瘤是卵巢癌（30.1%）。有治愈意向的患者中，80%获得了完全减瘤术（CC0/CC1）评分。总的死亡率为 20%。1 年和 4 年的总生存率（OS）分别为 89%和 54%。
CRS 和 HIPEC 在治疗选定的患者中最为成功。在这 8 年中，我们通过 CRS 实现了完全切除的进展，以及患者良好的 OS，这鼓励我们继续进行这项具有挑战性和高成本的手术。
